Can a patient with treatment-resistant depression on sertraline (Selective Serotonin Reuptake Inhibitor) 100mg and risperidone (Atypical Antipsychotic) 2mg be started on Wellbutrin (bupropion)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Adding Bupropion to Sertraline and Risperidone in Treatment-Resistant Depression

Direct Answer

Yes, bupropion (Wellbutrin) can be added to this patient's current regimen of sertraline 100mg and risperidone 2mg, as augmentation with bupropion has demonstrated superior efficacy in reducing depression severity compared to other augmentation strategies in treatment-resistant depression. 1

Evidence-Based Rationale

Bupropion as an Augmentation Strategy

  • Augmentation with bupropion decreases depression severity more than augmentation with buspirone, with lower discontinuation rates due to adverse events in patients who have failed initial SSRI treatment 2, 1

  • The American College of Physicians found no difference in response or remission rates when augmenting citalopram with bupropion versus buspirone, but bupropion showed superior reduction in depression severity scores 2

  • Multiple case reports and case series demonstrate successful combination therapy of SSRIs (including sertraline) with bupropion in treatment-refractory major depression, with synergistic effects on depressive symptoms 3, 4

Mechanism and Clinical Benefits

  • The combination of sertraline and bupropion provides complementary mechanisms: serotonergic activity from sertraline plus dopaminergic and noradrenergic activity from bupropion 4

  • This patient already has risperidone as an augmentation agent (an atypical antipsychotic), which aligns with National Institute of Mental Health recommendations for partial responders 1

  • Adding bupropion provides an additional mechanistic approach beyond the current SSRI-antipsychotic combination 3

Safety Considerations and Critical Warnings

Major caveat: There is documented risk of serotonin syndrome when combining bupropion with SSRIs, though this is rare 5

  • One case report described serotonin syndrome in a patient on therapeutic doses of bupropion and sertraline, attributed to bupropion's inhibition of cytochrome P450 2D6, which increases SSRI blood levels 5

  • Monitor closely for myoclonic jerks, confusion, agitation, autonomic instability, or altered consciousness—these may be misinterpreted as worsening depression 5

  • Bupropion lowers the seizure threshold; ensure this 69-year-old patient has no seizure risk factors and maintain total daily dose at or below 450mg in divided doses 6

  • Bupropion causes minimal anticholinergic effects and rare orthostatic hypotension, making it generally well-tolerated in elderly patients 6

Practical Implementation

  • Start bupropion at low doses (100mg once or twice daily) and titrate gradually over weeks to minimize seizure risk and allow assessment of tolerability 3, 6

  • Target dose typically ranges from 150-450mg daily in divided doses, with most treatment-resistant depression studies using 300-450mg daily 3, 4

  • Monitor response within 1-2 weeks of initiation and assess therapeutic response at 6-8 weeks, as recommended by the American College of Physicians for antidepressant modifications 2

  • Watch specifically for early signs of serotonin syndrome (myoclonus, confusion, autonomic changes) during the first few weeks after adding bupropion 5

Alternative Considerations

If bupropion augmentation fails or is not tolerated, the patient already has risperidone in place, which represents guideline-concordant augmentation with an atypical antipsychotic 1. The next steps would include optimizing risperidone dosing, considering lithium augmentation (requires monitoring), or exploring non-pharmacological options like cognitive behavioral therapy or electroconvulsive therapy 1.

References

Guideline

Treatment-Resistant Depression Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Bupropion and sertraline combination treatment in refractory depression.

Journal of psychopharmacology (Oxford, England), 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.